EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases

Juan Martin-Liberal, Iván Márquez-Rodas, Pablo Cerezuela-Fuentes, Ainara Soria, Fernando Garicano, Javier Medina, Regina García Galindo, Juana Oramas, José Luis Manzano, Mayte Delgado, Javier Valdivia, Pedro Sanchez

Cancer Treatment Reviews · 2025-02 · 133 · 102886

DOI: 10.1016/j.ctrv.2025.102886 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-02. Verfasst von Juan Martin-Liberal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Spain. Electronic address: jmartinliberal@iconcologia.net. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Brain Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Les Laboratories Pierre Fabre, Pierre Fabre Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global incidence of metastatic melanoma with BRAF mutations, characterized by aggressive behavior and poor prognosis, is rising. Recent treatment advances, including immune checkpoint inhibitors (ICI) and targeted therapies (TT) such as BRAF and MEK inhibitors, have significantly enhanced patient outcomes. Although guidelines recommend sequencing strategies, real-world implementation can be influenced by clinical scenarios. This article highlights the importance of tailored treatment strategies, emphasizing that the decision to initiate immunotherapy (IT) or TT hinges on multiple factors, including tumor burden, LDH levels, presence of brain metastases, and patient symptomatic status. Managing brain metastases also poses a challenge, as these patients are typically excluded from pivotal clinical trials. While insights from phase II studies provide some guidance, there is a critical need for more quality data to inform comprehensive recommendations. Furthermore, although triple therapy combining IT and TT was initially thought to be promising, it has failed to clearly demonstrate benefit over current treatments. For all these reasons, there is an imperative need for further research on biomarkers and predictive factors, as well as real-world studies, that will help tailor treatment strategies across diverse patient subsets, thereby refining therapeutic approaches for BRAF-mutated metastatic melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafBrain NeoplasmsSkin NeoplasmsHumansMutationMolecular Targeted TherapyImmunotherapyImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

BRAF-mutatedImmunotherapyMelanomaMetastaticTargeted therapyTreatment sequencing

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Spain. Electronic address: jmartinliberal@iconcologia.net.
  • Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
  • Virgen de la Arrixaca University Hospital, Ciudad de Murcia, Spain.
  • Ramón y Cajal University Hospital, Madrid, Spain.
  • Galdakao-Usansolo Hospital, Bilbao, Spain.
  • General University Hospital of Toledo, Toledo, Spain.

Förderung

  • Les Laboratories Pierre Fabre
  • Pierre Fabre Foundation

Zitieren

APA

Martin-Liberal, J., Márquez-Rodas, I., Cerezuela-Fuentes, P., Soria, A., Garicano, F., Medina, J., García Galindo, R., Oramas, J., Luis Manzano, J., Delgado, M., Valdivia, J., & Sanchez, P. (2025). Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases. Cancer Treatment Reviews, 133, 102886. https://doi.org/10.1016/j.ctrv.2025.102886

Vancouver

Martin-Liberal J, Márquez-Rodas I, Cerezuela-Fuentes P, Soria A, Garicano F, Medina J, et al. Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases. Cancer Treatment Reviews. 2025;133:102886. doi:10.1016/j.ctrv.2025.102886

BibTeX
@article{MartinLiberal2025,
  author = {Martin-Liberal, Juan and Márquez-Rodas, Iván and Cerezuela-Fuentes, Pablo and Soria, Ainara and Garicano, Fernando and Medina, Javier and García Galindo, Regina and Oramas, Juana and Luis Manzano, José and Delgado, Mayte and Valdivia, Javier and Sanchez, Pedro},
  title = {Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {133},
  pages = {102886},
  doi = {10.1016/j.ctrv.2025.102886}
}
Kostenlos starten →